Zimmer Biomet stock edges higher as YTD gains build and revenue grows
Published on 08/22/2026 at 12:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Zimmer Biomet Holdings Inc. (US98956P1021) stock is trading close to the $100 mark as of August 22, 2026, with the shares showing a double-digit gain since the start of the year and momentum backed by improving revenue trends.
Zimmer Biomet stock performance and valuation
Market data compiled from a live quote page shows Zimmer Biomet stock at $99.82 intraday on August 22, 2026, up 1.65% on the session at 10:53 a.m. Eastern Time. This quote snapshot indicates trading on the New York Stock Exchange with pricing in USD.
A broader performance view from a stock analysis portal notes that Zimmer Biomet shares were at $89.94 at the beginning of 2026 and are now trading around $99.10, representing a year to date increase of 10.2% as of August 21, 2026. The same analysis page also cites a current price in the high $99 range, consistent with real-time quotes.
Another market data source focused on daily trading statistics reports that Zimmer Biomet closed at $100.97 in the most recent completed session, with the stock touching a day high of $101.15 and a low of $98.74. According to that data as of August 21, 2026, the shares are 6.76% below the 52 week high of $108.29 and 27.62% above the 52 week low of $79.12, underscoring that the current level sits closer to the top of the recent trading range. The detailed share price overview also highlights that the stock has moved up 11.3% over the last month, adding a short term momentum angle to the year to date performance.
Fundamentals and recent revenue trend
Alongside the price move, fundamentals have shown mixed signals with revenue rising and net profit declining over recent quarters. One analytics summary covering the last two reported quarters states that revenue increased from $2.08 billion to $2.17 billion, with an average increase of 4.2% per quarter over that span. The same source notes that net profit fell from $238.10 million to $198.29 million over the two quarters, implying an average decrease of 16.7% per quarter. This metrics overview presents the figures as a recent trend, suggesting that Zimmer Biomet has been able to grow its top line while facing margin or cost pressures.
The combination of higher revenue and lower net profit makes the recent quarters particularly relevant for investors assessing operating leverage. Revenue growth from $2.08 billion to $2.17 billion represents an increase of $90 million, while net profit dropped by $39.81 million over the same span. That contrast implies that incremental sales have not yet translated into proportional earnings, which can focus attention on pricing, mix, and cost management in Zimmer Biomet's orthopedic and surgical portfolio.
Despite these mixed earnings dynamics, consensus valuation remains moderate. Data aggregated from analyst coverage and compiled on the same stock analysis portal indicates a consensus rating classified as Hold and an average target price of $104.42. One recent institutional holding report cites this average target, implying upside of several dollars from the current high $99 area if those targets are achieved.
Institutional interest and share positioning
Recent filings highlight active institutional positioning in Zimmer Biomet stock, which can influence liquidity and sentiment. A same day report on institutional holdings describes how one asset manager purchased 132,217 shares of Zimmer Biomet, with the filing noting that the shares were acquired as part of a measured position in the company. The institutional purchase summary points out that Zimmer Biomet stock opened at $101.01 in the referenced session, highlighting the trading level at which the position was initiated.
Another institutional update released on August 22, 2026, mentions that a separate wealth management firm took a $5.77 million position in Zimmer Biomet, further underscoring ongoing interest from professional investors. The position disclosure again references the same consensus Hold rating and $104.42 average target, linking institutional buying to a view that the stock offers balanced risk and reward at current levels.
From a positioning perspective, the combination of year to date price gains, recent monthly momentum of 11.3%, and steady institutional accumulation suggests that Zimmer Biomet is perceived as a core holding in the orthopedic device space rather than a high beta trade. The stock's current level roughly 6.76% below the 52 week high implies room for a potential retest of previous peaks if revenue growth persists and profit trends stabilize.
Product focus - Comprehensive Segmental Revision System
Zimmer Biomet's business is anchored in orthopedic implants and surgical solutions, and one illustrative product is the Comprehensive Segmental Revision System for shoulder and elbow reconstruction. The official product page describes this system as designed for cases involving significant distal humeral bone loss, providing components for elbow replacement alongside segmental options that help surgeons address complex revision scenarios. The product documentation emphasizes modularity and segmental reconstruction capabilities, which align with Zimmer Biomet's broader strategy of offering specialized implants that support challenging clinical cases in upper extremity orthopedics.
For investors, such specialized systems illustrate how Zimmer Biomet seeks to differentiate its portfolio by addressing specific surgical needs rather than relying solely on standard joint replacement solutions. Products like the Comprehensive Segmental Revision System can expand the addressable market in revision surgeries, where complexity and clinical risk are higher and implant choice is critical. This product context complements the numerical picture provided by recent revenue trends, offering a qualitative view of how Zimmer Biomet generates growth opportunities in its core orthopedic franchise.
Closing view on Zimmer Biomet shares
Zimmer Biomet shares trade on the New York Stock Exchange under the ticker ZBH with prices quoted in USD. As of the latest completed session on August 21, 2026, one detailed market overview reports a closing price of $100.97, with the stock 6.76% below its 52 week high of $108.29 and 27.62% above its 52 week low of $79.12. This places Zimmer Biomet stock in the upper segment of its recent range while still leaving a gap to prior peaks that could be closed if the company continues to grow revenue and stabilizes earnings margins.
Fact box
Company: Zimmer Biomet Holdings Inc.
ISIN: US98956P1021
Ticker: ZBH
Exchange: NYSE
Price (as of August 21, 2026, market close): $100.97 USD
Sector / Industry: Health care - Medical devices and equipment
Index membership: S&P 500
